Table 2.
Top ten canonical pathways for Grim-mAA-associated transcript genes
| Ingenuity canonical pathways | P | Molecules |
|---|---|---|
| Neuroinflammation signaling pathway | 1.59E−07 | AKT3, CD40, CREB3L4, CX3CL1, CX3CR1, CXCL10, FOS, GABRB2, GAD1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DQB2, IL1B, MR1, MYD88, NFKB1, NOX1, PIK3CG, SLC1A2, SOD2, TGFB1, TLR4, TLR5, TLR7, TYROBP |
| Estrogen biosynthesis | 1.68E−07 | AKR1B15, AKR1C1/AKR1C2, AKR1C3, AKR1C4, CYP1B1, CYP2A6 (includes others), CYP4F8, CYP4X1, HSD17B11, HSD17B13 |
| B cell development | 2.48E−07 | CD40, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DQB2, IL7R, PTPRC, RAG2 |
| ICOS-ICOSL signaling in T helper cells | 1.02E−06 | AKT3, CD4, CD40, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DQB2, IL2RG, ITPR1, LCP2, NFKB1, NFKBIA, PIK3CG, PLEKHA2, PTEN, PTPRC, TRGV8 |
| IL-17A signaling in airway cells | 2.82E−06 | AKT3, CCL20, CXCL1, CXCL3, MAP2K1, MUC5AC, NFKB1, NFKBIA, PIK3CG, PTEN, TRAF3IP2 |
| PD-1, PD-L1 cancer immunotherapy pathway | 4.27E−06 | AKT3, CDK2, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DQB2, IL2RG, LCP2, MR1, PIK3CG, PTEN, TGFB1 |
| Granulocyte adhesion and diapedesis | 9.19E−06 | CCL20, CCR2, CLDN1, CLDN10, CX3CL1, CXCL1, CXCL10, CXCL16, CXCL2, CXCL3, CXCL9, IL1B, ITGA4, MSN, SDC4, SELP, SELPLG |
| NRF2-mediated oxidative stress response | 9.40E−06 | ABCC1, CBR1, CYP2A6 (includes others), DNAJC14, FOS, GCLC, GCLM, GPX2, GSR, GSTA4, JUNB, MAP2K1, MAP2K6, NQO1, PIK3CG, PRDX1, SOD1, SOD2, TXNRD1 |
| PKCθ signaling in T lymphocytes | 1.32E−05 | CACNA1C, CACNA1D, CACNA2D3, CACNG4, CACNG6, CD4, FOS, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DQB2, ITPR1, LCP2, MAP3K9, NFKB1, NFKBIA, PIK3CG, TRGV8 |
| IL-17 signaling | 1.32E−05 | AKT3, CCL20, CXCL1, CXCL3, DEFB1, DEFB105A/DEFB105B, FOS, IL1B, MAP2K6, MUC5AC, NFKB1, PIK3CG, TGFB1, TNFSF13, TRAF3IP2, TRAF5, VEGFD |